China’s original new drug for Alzheimer’s disease approved, surprises clinicians

  1. The news that China’s original new medicine for Alzheimer’s disease has been approved has surprised clinicians. Alzheimer’s disease, a degenerative disease of the central nervous system that develops a hidden disease and develops a chronic progression, is the most common type of dementia in old age.

中国原创治疗阿尔茨海默病新药获批上市,让临床医生感到惊喜

The fourth of the commemorative stamps for “Technological Innovation (II)” issued by China Post on November 1st is GV-971, a new drug for the treatment of Alzheimer’s disease. Photo: Shanghai Post   

Statistics show that there are at least 50 million people with Alzheimer’s disease worldwide and are growing explosively, reaching 150 million by 2050. In China, the number of people with Alzheimer’s disease has exceeded 10 million, the highest in the world, and the annual number of new cases is increasing by more than 300,000.  

In an interview with reporters, Dr. Deng Weilei of the Neurology Department of Ruijin Hospital, affiliated with Shanghai Jiaotong University Medical College, said that Alzheimer’s disease has caused great social concern in the present, and the people’s attention to the disease is increasing year by year. On the opening of memory disorder clinic, at that time to see are moderate to severe patients, many patients can not take care of themselves, or even do not know family members, but now many patients in the early stages of the disease, found that memory than in the past decline, will immediately come to see a doctor. “

Deng said that with the development of aging, Alzheimer’s patients also from the past 50-60 years old, the scope of 60-90 years old, 80 years of age and older people are particularly common, the incidence rate is also increasing year by year.

“From the symptoms of this disease, memory loss is the most common clinical manifestation, in addition to language function decline, space recognition function, which can easily lead to loss or loss of patients, and some are poor logical ability, and even personality changes, these symptoms are easy to be ignored, in fact, this is also part of the symptoms of Alzheimer’s disease.” “It’s not like that.”

Because the pathogenesis is not clear, Alzheimer’s treatment has been clinical treatment difficultfor years, “the existing clinical treatment mainly has two major types of drugs, one is cholinesterase inhibitors, such as donaipyridine, heavy tatric acid kabaratin, and the other type of NMDA receptor coordinator, such as meratric acid, But the three drugs still can’t block or reverse the condition, only to alleviate the symptoms, Alzheimer’s disease new drug development 17 years no new progress, drugs like Mercure abroad in the late 1990s has been available. “

Why is it difficult to develop new drugs? Deng pointed out that this is mainly due to alzheimer’s disease pathogenesis is still unclear, “only to find the pathogenesis can block the progression of the disease, significantly improve the symptoms.” At present, the causes include genetic, trauma, encephalitis, etc., may also be associated with mental and emotional, the cause is very complex. It can be seen that its treatment also needs multi-angle, multi-target clinical research. “

The emergence of the Glynlut sodium capsule (GV-971), a drug that has conducted multicenter clinical studies in China, recruited 818 patients in Phase III clinical trials in 34 locations in China.

The Regin Hospital team, who also participated in the clinical study, said: “This study focused on double-blind, placebo-controlled studies as a new drug that, after six months of clinical validation, can significantly improve cognitive impairment in patients. We have just learned that Phase 9 I was approved by the National Drug Administration on 2 November 2019 and can be applied to mild to moderate patients with Alzheimer’s disease, and as clinicians we look forward to adding a powerful weapon to the fight against Alzheimer’s disease. “

Add a Comment

Your email address will not be published. Required fields are marked *